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Summary
We conducted a cross-sectional study from September 2001 to August 2003 during which children
between 2 and 12 years of age presenting with complaint of sore throat were recruited from urban
pediatric clinics in Brazil, Croatia, Egypt and Latvia. The objective of the study was to compare clinical
signs and symptoms of children presenting to urban pediatric clinics with sore throat in and between
countries and to identify common clinical criteria predicting group A beta hemolytic streptococcal
(GAS) pharyngitis. Using a single standard protocol in all four sites, clinical data were recorded and
throat swabs obtained for standard GAS culture in 2040 children. Signs and symptoms were tested for
statistical association with GAS positive/negative pharyngitis, and were compared using 2 tests,
ANOVA and Odds Ratios. Clinical signs of GAS pharyngitis in children presenting to clinics varied
significantly between countries, and there were few signs or symptom that could statistically be
associated with GAS pharyngitis in all four countries, though several were useful in two or three
countries. Our results indicate that the clinical manifestations of pharyngitis in clinics may vary by
region. It is therefore critical that clinical decision rules for management of pharyngitis should have
local validation.
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Introduction
Untreated group A beta hemolytic streptococcal
(GAS) pharyngitis is the precipitating cause of
rheumatic fever and subsequent rheumatic heart
disease, the most common cause of acquired heart
disease in children and adults worldwide [1, 2].
Despite having largely disappeared in high-income
countries, rheumatic heart disease continues to be
a significant public health problem in low-income
countries, causing an estimated 400 000 deaths
annually, mostly among children and young adults
[1, 3–5]. Current understanding of the epidemiology
and clinical features of GAS pharyngitis is largely
derived from studies conducted in high-income
(mostly Northern or temperate climate) countries
where rheumatic fever and rheumatic heart disease
are rare. In low-income countries, where rheumatic
fever and rheumatic heart disease continue to pose
significant public health problems, there are few
indexed prospective studies documenting the epide-
miology and clinical presentation of GAS
pharyngitis.
Throat culture is the internationally accepted gold
standard for the diagnosis [6]. However, in low-
income countries where financial resources limit the
widespread use of laboratory tests for GAS diag-
nosis, accurate clinical criteria are needed for the
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management of GAS pharyngitis. Earlier studies
have indicated that signs and symptoms of GAS
pharyngitis are often indistinguishable from those
observed in non-GAS pharyngitis [7, 8].
We initiated a prospective descriptive study to
define the variation in clinical presentation of GAS
pharyngitis within and between four countries to
determine if there is a group of common signs and/or
symptoms that could be used to accurately predict
GAS pharyngitis in children residing in geographi-
cally and culturally distinct regions.
Methods
Children were enrolled in four urban university
pediatric outpatient clinics from September 2001 to
August 2003 in Rio de Janeiro, Brazil; Cairo, Egypt;
Riga, Latvia and Zagreb, Croatia. Children between
2 and 12 years of age presenting to participating
outpatient clinics were screened for enrollment if
he/she presented with one or more of the following
complaints: cough, cold and/or sore throat. Exclu-
sion criteria included reports of one or more of the
following: oral antibiotic use within 3 days preceding
or intramuscularly administered antibiotics within
28 days prior to the clinic visit; a history of previous
rheumatic fever or rheumatic heart disease; or
hospitalization for any reason.
All study sites used a common study protocol,
standard methods for biological specimen collection
and laboratory analysis, and standard data collection
forms translated into the local language [9]. The
study protocol was approved by local and national
ethical review boards at each participating clinical
site, the World Health Organization in Geneva
and the Johns Hopkins Bloomberg School of Public
Health. Informed consent was obtained from the
parent or guardian accompanying the child to the
clinic and child assent was obtained from all partici-
pating children aged 5 years and older.
After enrollment, demographic data were recorded
and a physical examination was performed by
a pediatrician. In all sites, throat cultures were
obtained and plated onto 5% sheep blood agar
plates, incubated at 37C and examined at 24 and
48 h for the presence of beta-hemolytic streptococci
and confirmed by bacitracin disc [10].
In all sites, we conducted a standardization
exercise with participating clinicians to minimize
inter-rater variation in the identification of signs
and symptoms. The exercise consisted of a series of
clinical photographs of pharynges, which were shown
on a projection screen. Physicians were asked to
mark forms containing a list of collected signs
associated with streptococcal pharyngitis. Partici-
pants were asked to mark each sign as either absent,
present, not applicable or unknown for each clinical
photograph. A discussion followed the viewing and
assessment of signs, to clarify the characteristics and
severity of signs displayed in each photograph.
Statistical analysis
For the purpose of this analysis, we included only
children who presented with complaint of sore
throat. Demographic data was recorded for each
patient and compared with throat culture results.
Patients were categorized into either GAS positive or
GAS negative based on laboratory results of throat
swabs. Signs and symptoms among groups were
compared using 2 for proportions (adjusted for
multi-group comparisons) and ANOVA for compar-
ison of means. All analyses were conducted using the
statistical software STATA 9.0 [11].
Results
Patient characteristics
A total of 2040 children with complaint of sore
throat were enrolled at participating clinics. Demog-
raphic characteristics of these enrolled children
varied significantly by country. The proportion of
children with a positive GAS culture was 29.2%
overall, ranging from 26.8% in Brazil to 42.0% in
Croatia (p< 0.001). The mean age of patients for all
sites was 5.3 (2.6) years but means varied among
sites from 4.9 (0.06) in Egypt to 6.6 (0.38) in
Latvia (p< 0.001). The proportion of children below
the age of 5 was 41.7%, and varied among countries
from 31.5% in Latvia to 67.2% in Egypt (p< 0.001).
Female patients comprised 43.1% of the study
population, ranging from 42.0% in Croatia to
50.6% in Brazil (p¼ 0.197) (Table 1).
Clinical characteristics of GAS pharyngitis
Table 2 and Fig. 1 display the prevalence of signs and
symptoms commonly associated with streptococcal
pharyngitis in children enrolled in each country.
Clinical presentation of GAS pharyngitis varied
significantly between countries, and there were no
signs or symptoms that could statistically discrimi-
nate between patients with GAS and non-GAS
pharyngitis across all four countries. The age group
with the highest frequency of GAS pharyngitis was
5–9 years for all sites except Latvia, where it was
10–12 years of age. In Brazil, patients 5 years of age
were statistically more likely to be GASþ than those
<5 years (p< 0.001) though in Egypt and Latvia,
patients <5 years of age were more likely to be
GASþ than those 5 years of age (p< 0.005 and
p< 0.001, respectively). In Croatia there were no
statistically significant differences in incidence of
GAS pharyngitis between age groups. The peak
season for GAS pharyngitis varied by site. In Brazil,
which is in the southern hemisphere, fall and winter
were equally associated with GAS pharyngitis
(March–August). In Egypt and Croatia, the majority
A. W. RIMOIN ET AL.











Comparison of selected patient characteristics by site
Patient characteristics
Site GASþ % Female Age <5 years Mean age
n (%) n (%) n (%) (Years SD)
Brazil (n¼ 170) 44 (26.8) 86 (50.6) 90 (42.4) 5.5 0.2
Croatia (n¼ 200) 84 (42.0) 84 (42.0) 86 (32.0) 6.4 0.1
Egypt (n¼ 1410) 384 (27.3) 594 (43.1) 947 (52.8) 4.9 0.1
Latvia (n¼ 260) 77 (29.4) 119 (45.7) 81 (31.2) 6.6 0.4
P-value (2 or t-test) <0.001 0.106 <0.001 0.001
TABLE 2











Sign/Symptom n (%) OR p n (%) OR p n (%) OR p n (%) OR p
Fever 41 (91) 1.45 0.530 55 (67) 0.97 0.932 324 (84) 1.19 0.292 67 (88) 0.959 0.922
Chills 18 (40) 1.57 0.212 30 (36) 0.94 0.844 151 (39) 1.30 0.034 53 (69) 1.06 0.842
Rhinitis 14 (31) 0.49 0.054 39 (46) 0.75 0.328 171 (44) 0.66 0.001 26 (34.2) 0.89 0.675
Congestion 15 (33) 0.59 0.150 35 (42) 0.58 0.060 134 (35) 1.10 0.451 42 (55) 1.02 0.956
Difficulty swallowing 39 (87) 4.58 0.001 63 (75) 2.52 0.003 346 (90) 1.51 0.031 51 (67) 1.91 0.025
Cough 15 (33) 2.11 0.073 25 (30) 2.03 0.020 224 (58) 1.36 0.029 25 (33) 1.48 0.254
Vomiting 8 (18) 0.75 0.525 21 (25) 0.71 0.290 94 (24) 1.13 0.387 20 (26) 1.17 0.614
Hoarseness 14 (31) 1.31 0.480 31 (37) 1.07 0.821 100 (26) 1.29 0.068 32 (43) 3.28 <0.001
Cervical adenopathy 26 (58) 5.53 <0.001 46 (55) 2.06 0.013 88 (23) 1.49 0.007 59 (78) 1.56 0.164
Palatal petechiae 6 (13) 1.40 0.531 25 (30) 3.36 0.001 3 (1) 1.60 0.520 22 (29) 3.00 0.001
Strawberry tongue 45 (100) — — 18 (21) 2.60 0.021 8 (2) 1.67 0.266 26 (34) 1.64 0.095
Pharyngeal erythema 44 (90) 1.43 0.500 84 (100) — — 383 (100) 2.65 0.198 76 (98) 0.83 0.880
Enlarged tonsils 36 (74) 4.21 <0.001 84 (100) — — 290 (75) 1.19 0.211 63 (81) 1.37 0.356
Pharyngeal/tonsillar exudate 24 (49) 3.51 0.001 40 (48) 1.24 0.450 114 (30) 1.44 0.007 7 (9) 0.92 0.863
Highlighted box indicates statistically significant association (p< 0.05) with GASþ throat culture.





Difficulty swallowing X X X X 
Absence of cough X X 
Vomiting   
Hoarseness   X 
Cervical adenopathy X X X 
Palatal petechiae X X 
Strawberry tongue X
Erythema   
Enlarged tonsils X  
Exudate X  X 
 Brazil Croatia Egypt Latvia
FIG. 1. Signs/symptoms associated with GAS pharyngitis by country.
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of GAS pharyngitis cases occurred in the autumn
months between September and November. In
Latvia, the majority of cases of GAS pharyngitis
were observed in the winter, between December and
February. In Brazil, the majority of GAS pharyngitis
cases occurred in winter and spring months, which in
the southern hemisphere occured between April and
August. Fig. 2 displays the variation in the sensitivity
and specificity of the most common sign and symp-
tom in all four countries, showing the fairly wide
variation of these indices.
Discussion
In this study, the clinical presentation and rates of
GAS pharyngitis varied significantly by site. In our
study, the local fall and winter months were consis-
tently the peak times for GAS pharyngitis across
all sites, which differ from what has been previ-
ously reported in studies in temperate and tropical
regions. In temperate regions of the world, it has
been reported that the GAS incidence peaks during
the winter/spring months [12, 13]. In tropical regions
the peak incidence of GAS and non-GAS pharyngitis
is in March and April [14, 15].
Although the presenting signs and symptoms
of pharyngitis varied by site and by GAS status,
of particular interest was that some of the clinical
features of GAS pharyngitis in children widely cited
in textbooks, namely fever, pharyngeal erythema,
cervical adenopathy and palatal petechiae [8, 16] did
not usefully discriminate between GAS and non-
GAS pharyngitis in all participating study sites. This
finding has been observed in previous studies [17–19].
The only symptom that was statistically associated
with GAS pharyngitis in all four sites was diffi-
culty in swallowing. The sign of cervical adenopathy
was significantly associated with GAS pharyngitis
in three of the four countries: Brazil, Croatia and
Egypt, but not in Latvia. Absence of cough was
positively associated with GAS pharyngitis in
Croatia and Egypt; pharyngeal and/or tonsillar
exudate was positively associated with GAS phar-
yngitis in Brazil and Egypt; and palatal petechiae
were positively associated with GAS pharyngitis in
Croatia and Latvia.
Differences in clinical epidemiology of GAS phar-
yngitis have been shown by others to vary by geog-
raphy and climate [20]. Because our study included
four countries with diverse geography and climate we
are not able to consider the possibility that there may
be similarities in the clinical presentation and/or
epidemiology of GAS in countries within the same
region or with similar epidemiologic profiles. This
may be related to circulation of GAS strains and the
immunity profile of the various populations [21].
Our study had certain limitations. There were
differences in sample size in each study site. Egypt
had a significantly greater number of patients enrolled
than other sites due to the size of the participating
clinic and volume of patients who were eligible and
agreed to participate in the study. Additionally, since
the study was conducted in four distinct study sites
there may have been variations in the identification
of signs and symptoms by participating study physi-
cians. We used a common protocol, a common
training manual and a standardization exercise in all
four sites to control for this variation in physician
identification to the best of our ability. Similarly, there
may have also been differences in laboratory diagnosis
of GAS. We also used a common protocol, standard-
ized training and made supervisory visits to all partici-
pating sites to ensure standard laboratory methods.
Finally, variation in clinical presentation of GAS and
non-GAS pharyngitis between countries may have
been attributable to site specific differences in patient
recruitment and screening practices, number of
carriers with inter-current viral infections, popula-
tions served by participating health facilities, local
population access to care, care-seeking behavior and
cultural perceptions of sore throat.
Conclusions
In the United States and some industrialized
countries it is generally recommended that strepto-
coccal pharyngitis should be confirmed by laboratory
testing before antibiotic treatment if needed. How-
ever, laboratory testing is not feasible or available
in low resource regions of the world and clinicians
rely on clinical diagnosis to determine whether or not
to treat suspected GAS pharyngitis [8, 9, 22–24]. Our
results indicate that clinical signs and symptoms
associated with GAS pharyngitis vary substantially
by region, which suggests that developing a single
sensitive and specific clinical prediction rule for
all regions of the world would be a challenge [25].
Although some may feel it is impractical to suggest
that individual countries conduct national and/or
sub-national studies to determine the most common
local signs and symptoms of GAS, there is a need for
regional clinical data to determine valid indicators
for locally useful clinical prediction rules, validated
Swallow 
Cervical Adenopathy 
100 80 60 40 20 0 20 40 60 80 100
86 
21 
Sensitivity  Specificity 
36 75 
FIG. 2. Range of sensitivity and specificity of cervical
adenopathy and pain on swallowing, by site.
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decision rules are available for North America [9, 23,
24, 26]. This is particularly important in regions
where rheumatic fever and rheumatic heart disease
remain diseases of major public health significance.
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